Telo Genomics Corp. announced that John Price has been appointed as Chief Financial Officer, effective January 30, 2026. John Price has over three decades of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets.
His prior experience includes executive positions in several public companies including Assure Holdings, National Beverage, Alliance MMA, and MusclePharm. He also held various accounting and finance roles in high growth technology companies in Silicon Valley including Opera Software, GCT Semiconductor and Tessera Technologies. John Price spent the first seven years of his career with Ernst & Young.
He earned a Bachelor of Science in Accounting from Pennsylvania State University. John Price succeeds Christopher Ross who has served as the Company's CFO since April 2021.
